Windtree Therapeutics, Inc. (WINT)

US — Healthcare Sector

Peers: NRBO PALI LIXT ATXI CFRX

Automate Your Wheel Strategy on WINT

With Tiblio's Option Bot, you can configure your own wheel strategy including WINT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol WINT
Rev/Share 4.1341
Book/Share 1040.6982
PB 0.0079
Debt/Equity 1.3603
CurrentRatio 0.2461
ROIC -1.0817

MktCap 2745234.0
FreeCF/Share -1366.4676
PFCF -0.1846
PE -0.0004
Debt/Assets 0.0528
DivYield 0
ROE -3.2056

Rating C
Score 2
Recommendation Sell
P/E Score 1
DCF Score 1
P/B Score 5
D/E Score 1

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
No ratings available.

News

Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025

WINT
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral

Istaroxime has previously completed two positive Phase 2 studies in SCAI Stage B cardiogenic shock; the SEISMiC C study in SCAI Stage C cardiogenic shock is another step progressing to the istaroxime cardiogenic shock Phase 3 program

image for news Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025

Windtree Therapeutics Announces Presentation of Preclinical Data on Istaroxime and a Selective SERCA2a Activator at the European Society of Cardiology Heart Failure Conference May 17, 2025

WINT
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral

ePoster presentation advances the preclinical evaluation of the importance of SERCA2a function to reduce arrythmias with istaroxime and a selective SERCA2a activator in the setting of ischemia and reperfusion ePoster presentation advances the preclinical evaluation of the importance of SERCA2a function to reduce arrythmias with istaroxime and a selective SERCA2a activator in the setting of ischemia and reperfusion

image for news Windtree Therapeutics Announces Presentation of Preclinical Data on Istaroxime and a Selective SERCA2a Activator at the European Society of Cardiology Heart Failure Conference May 17, 2025

Windtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for US

WINT
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral

If istaroxime is granted the new chemical entity designation from FDA, it could provide 7.5 years of U.S. exclusivity and additionally the istaroxime U.S. issued method of use patent protects until 2039 for its planned initial indication in cardiogenic shock If istaroxime is granted the new chemical entity designation from FDA, it could provide 7.5 years of U.S. exclusivity and additionally the istaroxime U.S. issued method of use patent protects until 2039 for its planned initial indication in cardiogenic shock

image for news Windtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for US

Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics

EVFM, WINT
Published: March 26, 2025 by: PRNewsWire
Sentiment: Neutral

-- Evofem's Cost to Manufacture PHEXXI will Decrease by 55% - 60% -- SAN DIEGO , March 26, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) (Evofem or the Company) today announced that it has entered into a License and Supply Agreement (L&S Agreement) with Windtree Therapeutics, Inc. (NasdaqCM: WINT), under which Windtree will be Evofem's sourcing partner for PHEXXI® (lactic acid, citric acid and potassium bitartrate). This FDA-approved hormone-free contraceptive vaginal gel is applied 0 to 60 minutes before each act of intercourse.

image for news Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics

Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules

WINT
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral

WARRINGTON, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating biotech and advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that the Company received notice from The Nasdaq Stock Market LLC ("Nasdaq") that Windtree has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq. The Company will be subject to a mandatory panel monitor until March 20, 2026.

image for news Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules

Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product

EVFM, WINT
Published: March 20, 2025 by: GlobeNewsWire
Sentiment: Neutral

WARRINGTON, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating biotech and advancing early and late-stage innovative therapies for critical conditions and diseases, is pleased to announce that it has entered into a License and Supply Agreement to become the sourcing partner for Evofem Biosciences, Inc. (OTCQB: EVFM) for one of Evofem's FDA-approved products -- PHEXXI® (lactic acid, citric acid and potassium bitartrate).

image for news Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product

About Windtree Therapeutics, Inc. (WINT)

IPO Date 1995-08-07
Website https://windtreetx.com
Industry Biotechnology
CEO Mr. Jed A. Latkin
Employees 14

Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.